Clinical Genomics, a provider of cancer diagnostic solutions based in Bridgewater, has named Betsy Hanna its new CEO and president, it announced Thursday.
Hanna will also join the company’s board of directors, it said.
Hanna will succeed Dr. Lawrence LaPointe as CEO, who is transitioning into a new role as chief innovation officer. LaPointe will be responsible for developing solutions to improve clinical trials, research and development, and scientific developments. He will also continue to serve as an advisor to the board.
“Both Betsy and Larry bring enormous experience in their new roles. Betsy was most recently our chief commercial officer and has a 20-year career in healthcare turning products into commercial successes. Larry, as a co-founder and an accomplished scientist, will continue to lead our innovation in this rapidly evolving field,” Mary Padbury, Clinical Genomics’ board chairman, said.
Prior to her appointment, Hanna most recently served as chief commercial officer at Clinical Genomics. Before that, she was at Origin Inc. as its president and chief operating officer. She also spent time at Johnson & Johnson.
LaPointe previously served as chief technology officer and general manager of Enterix Inc.